



INTERNATIONAL JOURNAL OF EXPERIMENTAL AND BIOMEDICAL RESEARCH

Published by Pharma Springs Publication

Journal Home Page:

<https://pharmasprings.com/ijebr>

Methodology, Applications and Advancements of Car-T Cell Therapy in Malignancies

Ganne Goutham Sai*¹, Dusanapudi Swathi², Dorepalli Lalitha², Ganjala Tulasi²

¹V.V.Institute of Pharmaceutical Sciences, Seshadri Rao Knowledge, Krishna, near Railway Station, Gudlavalleru, Andhra Pradesh 521356, India

²Sri Vasavi Institute of Pharmaceutical Sciences, Pedatadepalli, Tadepalligudem - 534 101, West Godavari Dist., Andhra Pradesh, India

Article History:

Received on: 08 Mar 2024
Revised on: 20 Mar 2024
Accepted on: 25 Mar 2024

Keywords:

Cart -T Cell,
Malignancies,
Therapy and Advancement

Abstract

Despite significant advancements in cancer therapy, traditional treatments like radiation, chemotherapy, and surgery often fall short, underscoring the need for innovative approaches like activated cell therapy. Chimeric antigen receptor T cells (CAR-T cells) represent a pioneering form of this therapy, targeting cancer with modified T lymphocytes. While CAR-T cell therapy has shown high effectiveness in hematological malignancies, its success in solid tumors has been limited due to challenges such as proliferation, stability, trafficking, and tumor environment navigation. Overcoming these hurdles is crucial for enhancing the therapy's efficacy against solid tumors. The success rate of CAR-T cell therapy can reach up to 90% in leukemia patients, illustrating its potential. However, its application is still nascent, with much to learn about its long-term effectiveness and safety. This study provides an in-depth review of CAR-T cell therapy's accomplishments and limitations in cancer treatment and explores the potential of combining CAR-T cell therapy with other treatments.

*Corresponding Author

Name: Ganne Goutham Sai
Phone: +91 7207456469
Email: gouthamsai549@gmail.com

eISSN: 2583-5254

DOI: <https://doi.org/10.26452/ijebr.v3i2.593>

Production and hosted by

Pharmasprings.com

© 2024 | All rights reserved

INTRODUCTION

Recent years have seen a rapid development of cancer treatment techniques, with immunotherapy in particular emerging as one of the most quickly evolving therapeutic possibilities. Immunotherapy has progressively taken the lead as the primary therapeutic choice for malignant hematological disorders, and CAR-T cell immunotherapy has shown remarkable outcomes in the treatment of cancer [1]. All of the newest developments, including CB-010 therapy, to Kymriah and Yescarta, which were the first to be authorized by the FDA in August and October 2017 to treat leukemia and lymphoma, are crucial

in the treatment of malignant tumors, especially in situations of recurrence and resistant malignancies [2]. The spacer is required to join the transmembrane segment—an alpha helix found in the cell membrane—to the antigen recognition area. This segment connects the intracellular cytoplasmic domain to the extracellular antigen binding domain. Comprising of activation and co-stimulatory domains, the intracellular domain of the CAR represents its functional terminal [3]. In the cytoplasmic domain of CD3, ITAMs (immunoreceptor tyrosine-based activation motifs) are the most prevalent intracellular domain element. Specifically, the T cell receives an activation signal when an antigen binds with an antigen recognition domain. In addition, co-stimulatory signaling is necessary for T cell activation to be successful [4].




Figure 1: CAR T cell

STRUCTURE OF CAR-T CELL

The three primary parts of CAR are the intracellular, trans membrane, and extracellular domains. The signal peptide, a region that recognizes the tumor-associated antigen (TAA), consists of a spacer and an extracellular domain [5]. The variable part of the heavy (VH) and light (VL) chains of an antibody connected by a flexible linker is similar to the single-chain variable fragment (scFv) region that characterises the extracellular domain. The trans membrane section of the cell membrane, which is an alpha helix that connects the intracellular cytoplasmic domain to the extracellular antigen-binding domain, requires the spacer in order to connect the antigen recognition area to it [6]. The functional terminal

of the CAR, which typically contains activation and co-stimulatory domains, is known as the intracellular domain. Within the cytoplasmic domain of CD3, the most prevalent intracellular domain component is called an ITAMs (immune receptor tyrosine-based activation motifs). Specifically, an activation signal is given to the T cell when an antigen binds with an antigen identification domain. Furthermore, co-stimulatory signaling is necessary for T cell activation [7].




Figure 2: Structure of CAR T cell [8]

Fifth unique versions of CAR T cells have been identified based on the intracellular domain's shape. In order to maximize the intracellular domain of CAR structures, most CAR engineering efforts have often been focused on comprehending the consequences of CAR co-stimulation [9].

First generation CAR-T cell

When CARs were first developed, all that was needed for activation of T cells was the Fc receptor-chain (FCR), or CD3 chain from the CD3 TCR, coupled to an exogenous scFv. Additionally, prolonged cytokine production or effective T cell responses cannot be achieved by just talking with these regions [10]. Consequently, this generation of CARs was discontinued due to insufficient anticancer efficaciousness in vivo, strength, and signaling capability [11].

Second generation CAR-T cell

Early in the new millennium, second-generation CARs were created with the CD3ζ intracellular domain in sequence with a single co-stimulatory domain, such as CD 28 or 4-1BB (CD137), as the

significance of co-stimulation for the maintenance of CAR-T cell therapy became apparent. Clinical investigations have demonstrated that these intracellular signalling domains provide robust anti-cancer activity in patients with non-Hodgkin lymphoma and B-cell acute lymphoblastic leukaemia, and they also enhance T-cell persistence, secretion of cytokines, and anti-cancer efficiency in preliminary models [12].

Third generation CAR-T cell

Multiple co-stimulatory domains, such as CD28-41BB or CD28-OX40, were combined to create third-generation CARs, which increased the potency of CAR-T cells by producing more cytokines, having an anticancer effect, and promoting T-cell proliferation [13]. Furthermore, in comparison with second-generation CARs, several preclinical trials using third-generation CARs have shown to improve effectiveness, proliferation, and cytokine production in the clinic. On the other hand, data about whether patients respond better to second- or third-generation CAR T-cells is inconsistent [14].

Fourth generation CAR-T cell

Through the use of more recent, transgenic genetic changes, including transgenes for cytokine release and other co-stimulatory ligands, a fourth-generation kind of T cell-based immunotherapy was developed. Consequently, CAR-T cell activity and proliferation are enhanced by immunostimulatory cytokines like IL-2, which also increase the cells' resilience to the immunosuppressive tumor microenvironment. These cytokines also stimulate and attract the innate immune system to the site of the tumor [15].




Figure 3: Generations of CAR T cell

MECHANISM OF CAR-T CELL THERAPY

To express rebuilding of the CAR receptor for tumor-specific antigens, autologous T-cells are genetically modified as part of this therapy [16]. CARs are proteins that fusion together made up of the intracellular signaling domains of one or more T-cell receptors and the antigen-recognition portion of an antibody that is monoclonal. CAR-T cell treatment typically takes a few weeks to complete [17]. After removing autologous T-cells from the blood by leukapheresis, the cells are genetically modified ex vivo using both viral and non-viral transfection techniques. Ultimately, the patient receives another infusion of CAR T cells [18].




Figure 4: Methodology of CAR-T cell therapy

As that they attach to cancer cells, they can help eliminate the tumor cells by capturing a specific antigen on them. Through cytotoxicity, extensive cell multiplication, and increased cytokine, interleukin, and growth factor production, these cells destroy target cells [19].

ADVANCEMENTS OF CAR-T CELL THERAPY

For patients with advanced CLL, CAR-T cell treatment presents a challenge since the body's T cells become "tired" following chemotherapy. JQ1 was recently employed as an investigational medication by University of Pennsylvania researchers to suppress the BET protein, enhancing the capabilities of CAR-T cells. Kong et al. shown how the BET protein can interfere with T cell CAR production and important acetylated histone activities in CLL patients [20].

TET2 methylcytosine dioxygenase levels are suppressed by BET protein inhibition, and increased BET protein targeting in CAR-T cells is eliminated by compelled expression of the TET2 catalytic domain. By focusing on two or more tumor-related chemicals, cancerous cells may be kept from escaping the immune system. Spiegel *et al.* assessed forty-four LBCL patients undergoing conventional CD19 CAR-T cell treatment. Of these, 89% had pretreatment cancer cells with significantly expressed CD19 on their surface. Among all LBCL patients, around half had progression of the disease [21].

Furthermore, at the time of relapse, 9 out of 15 (or 60%) had changed from CD19-positive to CD19-negative or low levels, indicating that these lymphoma cells may have eluded therapy [22].




Figure 5: Advance developments with CAR-T cells

Spiegel *et al.* also discovered that patients were more likely to respond favorably to treatment if they had more than about 3000 CD19 molecules per cancer cell surface, whereas patients with less CD19 individuals are more likely to experience a recurrence following an effective course of therapy [23].

CAR-T CELL COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR

The existence of immunosuppressive TME is one of the issues with CAR T cell treatment in solid malignancies, as was previously highlighted. This immunosuppressive microenvironment is the result of several causes, includes inhibiting substances like PD-1, CTLA-4, LAG-3, etc. One the

other hand, the FDA has approved the use of monoclonal antibodies as an immunotherapy targeting these molecules (immune checkpoint inhibition), which has demonstrated potent anti cancer benefits [24]. However, recent research have demonstrated that the efficacy of CAR T cell treatment can be significantly increased by combining these ICBs with CAR T cells.

Antibodies like these can keep CAR T cells from becoming exhausted and enable them to continue acting as effectors [25].

CONCLUSION

Self-reproducing cells called CAR-T cells have advanced the treatment of cancer in notable ways. One example of how basic research is being applied to clinical practice is the development of CAR T cell therapy.

In general, the ability of CAR-T cells to be produced efficiently and delivered safely determines their use for cancer treatment. In general, the ability of CAR-T cells to be produced efficiently and delivered safely determines their use as cancer treatment.

Significant progress in the management of toxicity associated with CAR-T cell treatment might be achieved by better understanding the toxicity mechanism. The primary objective of CAR therapy is to explore its potential in nonhematological cancers, despite the fact that it has demonstrated notable efficacy in hematological malignancies. It appears that new approaches to immunotherapy will be necessary to get over the numerous challenges that CAR-T cell treatment in solid tumors must overcome. In the treatment of solid tumors, anti-tumor medications such as immune checkpoint inhibitors, radiation, chemotherapy, and oncolytic viruses may be used in combination with CAR-T cell therapy. Nevertheless, it does not appear to be easy to choose which oncolytic viruses are suitable for use in combination with CAR therapy given the wide range of viruses that are now accessible. Generally speaking, CAR success rates differ according on the kind of cancer. But since this kind of immunotherapy is still relatively new, there is still a lot to learn about its effectiveness.

ACKNOWLEDGEMENT:

The Authors of the article are thankful to the principal Dr. A Lakshmana Rao from V.V. Institute of Pharmaceutical Sciences, Seshadri Rao Knowledge, Krishna, near Railway Station, Gudlavalleru, India for providing necessary facilities to publish this review article.

Conflict of Interest

The authors declare no conflict of interest, financial or otherwise.

Funding Support

The authors declare that they have no funding for this study.

REFERENCES

- [1] Miliotou AN, Papadopoulou LC, et al. CAR T-cell therapy: a new era in cancer immunotherapy. *Current Pharmaceutical Biotechnology*. 2018;19 (1):5–18
- [2] Han X, Wang Y, Wei J, Han W, et al. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy. *Journal of Hematology and Oncology*. 2019;12(1):1–10.
- [3] Ruhlmann CH, et al. Multinational study exploring patients' perceptions of side-effects induced by chemo-radiotherapy. *Radiotherapy and Oncology*. 117(2):333–337, 2015.
- [4] O'Donnell JS, Teng MWL, Smyth MJ, et al. Cancer immunoediting and resistance to T cell-based immunotherapy. *Nature Reviews and Clinical Oncology*. 2019;16(3):151–167.
- [5] Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, et al. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. *Blood*. 2022;139(12):1794–806.
- [6] Whitlow M, Bell BA, Feng S, Filpula D, Hardman KD, Hubert SL, et al. An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. *Protein Engineering Design and Selection*. 1993;6(8):989–995.
- [7] Han D, Xu Z, Zhuang Y, Ye Z, Qian Q, et al. Current Progress in CAR-T cell therapy for hematological malignancies. *Journal of Cancer*. 2021;12(2):326–334.
- [8] Atrash S, Moyo TK, et al. A review of chimeric antigen receptor t-cell therapy for myeloma and lymphoma. *Oncology Targets and Therapeutics*. 2021;14:2185.
- [9] Safarzadeh Kozani P, Naseri A, Mirarefn SMJ, Salem F, Nikbakht M, Evazi Bakhshi S, et al. Nanobody-based CAR-T cells for cancer immunotherapy. *Biomark Research*. 2022;10(1):1–18.
- [10] Muyldermans S. et al. Nanobodies: natural single-domain antibodies. *Annual Reviews and Biochemistry*. 2013;82(1):775–97
- [11] Greenberg AS, Avila D, Hughes M, Hughes A, McKinney EC, Flajnik MF, et al. A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. *Nature*. 374(6518):168–173, 1995.
- [12] Brudno JN, Lam N, Vanasse D, Shen Y, Rose JJ, Rossi J, et al. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. *Nature Medicine*. 2020;26(2):270–80.
- [13] Bridgeman JS, Hawkins RE, Bagley S, Blaylock M, Holland M, Gilham DE, et al. The optimal antigen response of chimeric antigen receptors harboring the CD3 transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. *Journal of Immunology*. 2010;184(12):6938–6949.
- [14] Xu X, et al. NKT cells coexpressing a GD2-specific chimeric antigen receptor and IL15 show enhanced in vivo persistence and antitumor activity against neuroblastoma. *Clinical Cancer Research*. 2019;25(23):7126–7138
- [15] Pule MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK, et al. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. *Molecular Therapy*. 2005;12(5):933–941.
- [16] Song D, Ye Q, Poussin M, Harms GM, Figini M, Powell DJ Jr, et al. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. *Blood*. 2012;119(3):696–706.
- [17] Guedan S, Chen X, Madar A, Carpenito C, McGettigan SE, Frigault MJ, et al. ICOS-based chimeric antigen receptors program bipolar

TH17/ TH1 cells. *Blood*. 2014;124(7):1070–80.

- [18] Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. *New England Journal of Medicine*. 2017;377(26):2531–2544.
- [19] Porter DL, Hwang W, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. *Science Translation Medicine*. 2015;7(303):139r–303r
- [20] Kawalekar OU, O Connor RS, Fraietta JA, Guo L, SE MG, Posey AD Jr, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. *Immunity*. 2016;44(2):380–390.
- [21] Friedman KM, Garrett TE, Evans JW, Horton HM, Latimer HJ, Seidel SL, et al. Effective targeting of multiple B-cell maturation antigen-expressing hematological malignancies by anti-B-cell maturation antigen chimeric antigen receptor T cells. *Human Gene Therapy*. 2018;29(5):585–601.
- [22] Philipson BI, O Connor RS, May MJ, June CH, Albelda SM, Milone MC, et al. 4-1BB costimulation promotes CAR T cell survival through noncanonical NF- κ B signaling. *Science Signal*. 2020;13(625):y8248.
- [23] Feucht J, Sun J, Eyquem J, Ho Y, Zhao Z, Leibold J, et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. *Nature Medicine*. 2019;25(1):82–88.
- [24] Ramello MC, Benzaïd I, Kuenzi BM, Lienlaf-Moreno M, Kandell WM, Santiago DN, et al. An immunoproteomic approach to characterize the CAR interactome and signalosome. *Science Signal*. 2019;12(568):p9777.
- [25] Eshhar Z, Waks T, Gross G, Schindler DG, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. *Proceedings National Academy Science*. 1993;90(2):720–724.

Commons Attribution-Noncommercial- Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.



© 2024 Pharma Springs Publication

Copyright: This is an open access article distributed under the terms of the Creative